Gorovitz & Borten, P.C.
Attorneys at Law

400-1 Totten Pond Road
Waltham, Massachusetts 02451
Tel: (781) 890-9095
Colorectal Cancer
Colorectal cancer is the third leading cause of cancer and the second leading
cause of all cancer-related deaths in the United States. Each year approximately
145,000 new cases of colorectal cancer are diagnosed in the United States
(105,000 new cases of colon cancer and 40,000 new cases of rectal cancer). The
lifetime chances of developing colorectal cancer is approximately 5%. Combined,
these two types of cancer cause 56,000 deaths per year. The frequency of colon
cancer is essentially the same among men and women. Signs and symptoms
associated with colorectal cancer include:

  • Rectal bleeding (overt or occult)
  • Change in bowel habits
  • Mucus per rectum
  • Abdominal pain
  • Weight loss

If detected early, colon and rectal cancer are curable by surgery. Long-term
survival correlates with the stage at diagnosis of the disease in colorectal cancer.
Progress has been made in understanding the basis for predisposition and
progression of colorectal cancer. Risk factors for colorectal cancer include:

  • Age
  • Diet rich in fat and cholesterol
  • Inflammatory bowel disease (ulcerative colitis)
  • Alcohol ingestion in rectal cancer
  • Genetic predisposition (hereditary polyposis and nonpolyposis syndromes)

Hereditary nonpolyposis colorectal cancer (HNPCC) is the most common known
hereditary cause of colon cancer. HNPCC is hereditary and involves a mutation in
one of five different genes and is also known as Lynch Syndrome. About 1% to 5%
of colon cancers are attributed to HNPCC. A patient with HNPCC has up to 80%
chance of developing colon cancer during their lifetime. The mean age for
someone with HNPCC developing colorectal cancer is 44 years. Cancers tend to be
on the right (ascending) colon, are poorly differentiated and mucus producing.
Genetic testing and screening in these individuals with HNPCC for colon cancer
should be started as early as 20-22 years of age.

The vast majority of colorectal cancers are adenocarcinomas which arise from a
preexisting adenomatous polyp(s) that develop in the normal colon mucosa. The
progression sequence from adenoma to carcinoma is a well characterized clinical
and histopathological series of events. Convincing evidence of increased early
detection resulting in a reduced colorectal cancer mortality supports the use of
specific screening guidelines which include:

  • Colonoscopy
  • Flexible sigmoidoscopy
  • Barium enema
  • Fecal occult blood test
  • Carcinoembryonic antigen (CEA)
  • Digital rectal examination

Failure to adhere to the acceptable screening guidelines can result in a significant
delay in the diagnosis of colon and rectal cancer, depriving a patient of a
meaningful chance of cure and a better quality of life.

The overall 5 year survival rate from colon cancer is approximately 60%. the 5 year
survival rate is different for each stage of the disease at the time of diagnosis.
Several classifications are utilized to stage colon cancer. The Dukes and TNM
System are the most widely used.

Dukes (modified) Classification

  • Stage A:   Carcinoma confined to the wall of the bowel
  • Stage B:   Carcinoma spread by direct continuity to perirectal or pericolonic
                       tissue; no lymph node metastasis
  • Stage C:   Metastasis present in regional lymph nodes
  • Stage D:   Omental implant; peritoneal seeding; metastasis beyond the
                       confines of surgical resection

Tumor-Node-Metastasis (TNM) System

  • TNM  0:   Tis, N0, M0
  • TNM   I:    T1, N0, M0 & T2, N0, M0
  • TNM  II:    T3, N0, M0 & T4, N0, M0
  • TNM III:     Any T, N1, M0 & Any T, N2, M0
  • TNM IV:    Any T, Any N, M1

For Dukes stage A tumors involving only the mucosa, the 5 year survival rate
exceeds 90%; For Dukes stage B colon cancers, the 5 year survival rate is greater
than 70% and can get to be better than 80% if the tumor does not penetrate the
muscularis mucosa; For Dukes stage C with lymph nodes involvement, the 5 year
survival rate is usually less than 60%; and for metastatic colon cancer, the 5 year
survival rate is about 5%.

If you (or a loved one) are suffering from complications due to a failure to timely
diagnose, delayed diagnosis or misdiagnosis of  colon or rectal cancer, or the
recommended screening guidelines were not followed, let
Dr. Borten and the
Boston area medical malpractice attorneys at Gorovitz & Borten evaluate your
case. We can help you assert your rights and get the compensation you deserve.
Contact Information
For a free confidential consultation and receive a response within 24 hours (when
possible), please contact us by phone, fax or e-mail with your question or concern.

Telephone:  781-890-9095     -     Fax:   781-890-9098
                                                                                               
Directions
Electronic mail:
Questions or Inquiries to:
inquiry@gbmedlaw.com

Website disclaimer: The materials on this website have been prepared by Gorovitz &
Borten, P.C. for informational purposes only and are not intended, and should not be construed
as legal advice. This information is not intended to create and receipt of it does not constitute a
lawyer-client relationship. Similarly, any submission or receipt of information using electronic
"Contact Us" form does not create a lawyer-client relationship. Internet and online readers should
not act upon any of the information contained on this website without seeking professional
counsel. (
See Terms and Conditions).